[Lipodystrophies: what treatment?].
Vigouroux
C
C
INSERM U402, Faculté de Médecine Saint-Antoine, Service de Biochimie-Hormonologie, Hôpital Tenon, Paris, France.
D000998:Antiviral Agents / Q000009:adverse effects; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000628:therapy; D004032:Diet; D015444:Exercise; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones
D000998:Antiviral Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; C089946:2,4-thiazolidinedione